Information Provided By:
Fly News Breaks for December 12, 2019
Dec 12, 2019 | 16:27 EDT
Oppenheimer analyst Esther Rajavelu initiated coverage of Ionis Pharmaceuticals with an Outperform rating and $77 price target. The analyst is positive on the company's "solid base business of revenue-generating assets", along with its "broadly applicable discovery platform" and strategic partnerships, saying the stock offers a diversified opportunity in the RNAi sub-segment of biotechnology, and stands "well positioned for growth with its current portfolio of commercialized assets". Rajavelu also cites Ionis Pharma's "incremental value inflection" opportunities through its developing pipeline.
News For IONS From the Last 2 Days
There are no results for your query IONS